The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Exploring And Exploiting Novel Therapeutic Avenues In Mesothelioma
Funder
National Health and Medical Research Council
Funding Amount
$425,048.00
Summary
Mesothelioma is a fatal cancer of the lungs. It rapidly grows and invades surrounding tissues such as the ribcage, causing severe shortness of breath and pain. Chemotherapy has limited effect and although immunotherapy appears promising, most patients do not respond. I will investigate why mesothelioma is so invasive; how to improve the response to immunotherapy and how to best combine chemotherapy and immunotherapy. I aim to develop new treatments that will benefit patients with mesothelioma.
Improving Management Of Bone Health Of Cancer Survivors
Funder
National Health and Medical Research Council
Funding Amount
$178,722.00
Summary
Many cancer treatments predispose to bone loss leading to higher risk of fractures, pain and disability and concerns regarding cancer recurrence and unnecessary worry and distress. Current management of bone health in cancer survivors is variable and not well integrated into the overall cancer care. This project aims to improve management of bone health in cancer survivors by incorporating evidence for bone health management into the existing patterns of care of cancer survivors.
I am a clinician-scientist engaged in basic, translational and clinical breast cancer research, with the long-term goal to identify and exploit novel cancer targets to improve patient outcomes. My research, which covers both sporadic and hereditary forms of breast cancer, is focussed on elucidating the breast epithelial cell hierarchy, in order to identify key regulators responsible for breast epithelial cell proliferation, differentiation and cancer.
Compartmental Analysis Of T-cell Responses In Thoracic Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$851,403.00
Summary
To improve immune therapy for cancer we have to be able to determine how cancer patients ‘see’ mutated cancer proteins. Blood is the easiest & most useful source of immune ‘killer’ cells for that task, but the lymph node that drains the tumour and the fluid that bathes a tumour probably contain a much higher number of these killer cells than blood. If so, studying them would help us better track responses to therapy and enable us to choose the best mutated proteins for a vaccine.
Improving Sexual Health In Men With Prostate Cancer: Randomised Controlled Trial Of Exercise And Psychosexual Therapies
Funder
National Health and Medical Research Council
Funding Amount
$583,416.00
Summary
Sexual dysfunction is one of the most common and distressing side effects of prostate cancer. Despite being a critical survivorship care issue, there is a clear gap in knowledge surrounding the optimal treatment of sexual dysfunction in men with prostate cancer. This project examines whether exercise aids in the management of sexual dysfunction and explores if an integrated treatment model incorporating pharmacological, exercise and psychosexual therapies maximises improvement in sexual health.
The CRE is a collaboration of researchers who have a national and strategic focus for research into asbestos related diseases and cancers. The National Centre for Asbestos Related Diseases provides a platform to build on Australia’s existing research expertise and encourages strong organisational linkages to ensure our research is systematic and complementary to existing research efforts in the area of asbestos related diseases.
Immunotherapy In Mismatch Repair-deficient Colorectal Cancers
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
A new drug called PD-1 is effective in treating bowel cancers occurring in people at high risk of cancer called Lynch syndrome but little is known why PD-1 is effective at treating these cancer types. Initial studies have found that certain attributes of these cancers such as high amounts of inflammation may help to predict why these cancers respond to PD-1 but further studies of these tumors are needed to identify other tumor characteristics that may help predict responsiveness to PD-1.